Management ChangeJul 15, 2026, 07:01 AM
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
AI Summary
BioCryst Pharmaceuticals announced the appointment of David W. Jenkins, MA, PhD, as its new Chief Scientific Officer, effective immediately. Dr. Jenkins will lead a research team focused on leveraging external innovation, capabilities, and partnerships to accelerate the delivery of rare disease therapies. This appointment reinforces BioCryst's strategic pivot in R&D towards high-impact external opportunities and building a high-value pipeline.
Key Highlights
- BioCryst Pharmaceuticals appointed David W. Jenkins, MA, PhD, as Chief Scientific Officer, effective immediately.
- Dr. Jenkins will report to Dr. Sandeep Menon, Chief Research and Development Officer.
- His role involves building and leading a research team focused on external innovation and partnerships for rare disease therapies.
- Dr. Jenkins brings over 20 years of biopharmaceutical industry experience in R&D and external innovation.
- He previously served as Senior Vice President, Head of Research & External Innovation at Ipsen.
- Under his leadership at Ipsen, more than 35 assets were added to the pipeline across therapeutic areas.
Price Impact
More from BCRX